A higher percentage of AQP4-ON patients had comorbidities such as Sjögren’s syndrome and systemic lupus erythematosus compared to MOG-ON patients (6/20 [30.0%] vs. 0/26[0.0%]; p = 0.004). This evidence concerns the gene AQP4 and Sjogren syndrome.